

CHLD0071: Molecular and Clinical Aspects of Childhood Cancers

View Online



[1]

R. A. Weinberg, *The biology of cancer*, 2nd ed. New York: Garland Science, 2014.

[2]

D. Hanahan and R. A. Weinberg, 'The Hallmarks of Cancer', *Cell*, vol. 100, no. 1, pp. 57-70, Jan. 2000, doi: 10.1016/S0092-8674(00)81683-9.

[3]

D. Hanahan and R. A. Weinberg, 'Hallmarks of Cancer: The Next Generation', *Cell*, vol. 144, no. 5, pp. 646-674, Mar. 2011, doi: 10.1016/j.cell.2011.02.013.

[4]

C. J. Lord and A. Ashworth, 'Biology-driven cancer drug development: back to the future', *BMC Biology*, vol. 8, no. 1, 2010, doi: 10.1186/1741-7007-8-38.

[5]

B. Vogelstein, N. Papadopoulos, V. E. Velculescu, S. Zhou, L. A. Diaz, and K. W. Kinzler, 'Cancer Genome Landscapes', *Science*, vol. 339, no. 6127, pp. 1546-1558, Mar. 2013, doi: 10.1126/science.1235122.

[6]

T. I. Lee and R. A. Young, 'Transcriptional Regulation and Its Misregulation in Disease', *Cell*,

vol. 152, no. 6, pp. 1237–1251, Mar. 2013, doi: 10.1016/j.cell.2013.02.014.

[7]

'Children's cancer statistics | Cancer Research UK'. [Online]. Available:
<http://www.cancerresearchuk.org/health-professional/cancer-statistics/childrens-cancers>

[8]

International Agency for Research on Cancer, WHO classification of tumours of the central nervous system, Revised 4th edition. Lyon: International Agency for Research on Cancer, 2016.

[9]

Taylor, Michael DNorthcott, Paul AKorshunov, AndreyRemke, MarcCho, Yoon-jae, 'Molecular subgroups of medulloblastoma: the current consensus', *Acta Neuropathologica*, vol. 123, no. 3, pp. 465–72 [Online]. Available:
https://search.proquest.com/docview/928783888?rfr_id=info%3Axri%2Fsid%3Aprimo

[10]

P. Gibson et al., 'Subtypes of medulloblastoma have distinct developmental origins', *Nature*, vol. 468, no. 7327, pp. 1095–1099, Dec. 2010, doi: 10.1038/nature09587.

[11]

D. W. Ellison et al., ' β -Catenin Status Predicts a Favorable Outcome in Childhood Medulloblastoma: The United Kingdom Children's Cancer Study Group Brain Tumour Committee', *Journal of Clinical Oncology*, vol. 23, no. 31, pp. 7951–7957, Nov. 2005, doi: 10.1200/JCO.2005.01.5479.

[12]

Nataliya Zhukova, 'Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma', *Journal of Clinical Oncology*, vol. 31, no. 23, 2013, doi: 10.1200/JCO.2012.48.5052. [Online]. Available:
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878050/>

[13]

T. J. Stone and T. S. Jacques, 'Medulloblastoma: selecting children for reduced treatment', *Neuropathology and Applied Neurobiology*, vol. 41, no. 2, pp. 106–108, Feb. 2015, doi: 10.1111/nan.12193.

[14]

E. C. Schwalbe et al., 'Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study', *The Lancet Oncology*, vol. 18, no. 7, pp. 958–971, Jul. 2017, doi: 10.1016/S1470-2045(17)30243-7.

[15]

S. Pfister et al., 'Novel genomic amplification targeting the microRNA cluster at 19q13.42 in a pediatric embryonal tumor with abundant neuropil and true rosettes', *Acta Neuropathologica*, vol. 117, no. 4, pp. 457–464, Apr. 2009, doi: 10.1007/s00401-008-0467-y.

[16]

Korshunov, AndreySturm, DominikRyzhova, MarinaHovestadt, VolkerGessi, Marco, 'Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity', *Acta Neuropathologica*, vol. 128, no. 8, pp. 279–89 [Online]. Available: <https://search.proquest.com/docview/1545765655?OpenUrlRefId=info:xri/sid:primo&aaccountid=14511>

[17]

Ed. C. Schwalbe et al., 'Histologically defined central nervous system primitive neuro-ectodermal tumours (CNS-PNETs) display heterogeneous DNA methylation profiles and show relationships to other paediatric brain tumour types', *Acta Neuropathologica*, vol. 126, no. 6, pp. 943–946, Dec. 2013, doi: 10.1007/s00401-013-1206-6.

[18]

D. Sturm et al., 'New Brain Tumor Entities Emerge from Molecular Classification of

CNS-PNETs', *Cell*, vol. 164, no. 5, pp. 1060–1072, Feb. 2016, doi:
10.1016/j.cell.2016.01.015.

[19]

Kirsti Sirkiä, Ulla M. Saarinen-Pihkala, Liisa Hovi, Hannu Sariola, 'Autopsy in children with cancer who die while in terminal care', *Medical and Pediatric Oncology*, vol. 30, no. 5, pp. 284–289, 1998, doi: 10.1002/(SICI)1096-911X(199805)30:5<284::AID-MPO4>3.0.CO;2-B. [Online]. Available: [https://onlinelibrary.wiley.com/doi/abs/10.1002/\(SICI\)1096-911X\(199805\)30:5%3C284::AID-MPO4%3E3.0.CO;2-B](https://onlinelibrary.wiley.com/doi/abs/10.1002/(SICI)1096-911X(199805)30:5%3C284::AID-MPO4%3E3.0.CO;2-B)

[20]

T. Buckner, J. Blatt, and S. V. Smith, 'The Autopsy in Pediatrics and Pediatric Oncology: A Single-Institution Experience', *Pediatric and Developmental Pathology*, vol. 9, no. 5, pp. 374–380, Sep. 2006, doi: 10.2350/06-02-0047.1.

[21]

L. F. Bleggi-Torres et al., 'Accuracy of the smear technique in the cytological diagnosis of 650 lesions of the central nervous system', *Diagnostic Cytopathology*, vol. 24, no. 4, pp. 293–295, Apr. 2001, doi: 10.1002/dc.1062.

[22]

R. M. Hill et al., 'Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease', *Cancer Cell*, vol. 27, no. 1, pp. 72–84, Jan. 2015, doi: 10.1016/j.ccell.2014.11.002.

[23]

I. Blümcke et al., 'Low-grade epilepsy-associated neuroepithelial tumours — the 2016 WHO classification', *Nature Reviews Neurology*, vol. 12, no. 12, pp. 732–740, Dec. 2016, doi: 10.1038/nrneuro.2016.173.

[24]

S. Chhabda, O. Carney, F. D'Arco, T. S. Jacques, and K. Mankad, 'The 2016 World Health

Organization Classification of tumours of the Central Nervous System: what the paediatric neuroradiologist needs to know', *Quantitative Imaging in Medicine and Surgery*, vol. 6, no. 5, pp. 486–489, Oct. 2016, doi: 10.21037/qims.2016.10.01.

[25]

J. Schwartzentruber et al., 'Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma', *Nature*, vol. 482, no. 7384, pp. 226–231, Feb. 2012, doi: 10.1038/nature10833.

[26]

D. Sturm et al., 'Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma', *Cancer Cell*, vol. 22, no. 4, pp. 425–437, Oct. 2012, doi: 10.1016/j.ccr.2012.08.024.

[27]

P. W. Lewis et al., 'Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma', *Science*, vol. 340, no. 6134, pp. 857–861, May 2013, doi: 10.1126/science.1232245.

[28]

S. Bender et al., 'Reduced H3K27me3 and DNA Hypomethylation Are Major Drivers of Gene Expression in K27M Mutant Pediatric High-Grade Gliomas', *Cancer Cell*, vol. 24, no. 5, pp. 660–672, Nov. 2013, doi: 10.1016/j.ccr.2013.10.006.

[29]

R. Hashizume et al., 'Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma', *Nature Medicine*, vol. 20, no. 12, pp. 1394–1396, Dec. 2014, doi: 10.1038/nm.3716.

[30]

M. Pathania et al., 'H3.3K27M Cooperates with Trp53 Loss and PDGFRA Gain in Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas', *Cancer Cell*, vol. 32, no. 5, pp. 684–700.e9, Nov. 2017, doi: 10.1016/j.ccell.2017.09.014.

[31]

J. D. Larson et al., 'Histone H3.3 K27M Accelerates Spontaneous Brainstem Glioma and Drives Restricted Changes in Bivalent Gene Expression', *Cancer Cell*, Dec. 2018, doi: 10.1016/j.ccell.2018.11.015.

[32]

J. P. Martinez-Barbera and C. L. Andoniadou, 'Concise Review: Paracrine Role of Stem Cells in Pituitary Tumors: A Focus on Adamantinomatous Craniopharyngioma', *STEM CELLS*, vol. 34, no. 2, pp. 268–276, Feb. 2016, doi: 10.1002/stem.2267.

[33]

J. M. Gump et al., 'Identification of targets for rational pharmacological therapy in childhood craniopharyngioma', *Acta Neuropathologica Communications*, vol. 3, no. 1, Dec. 2015, doi: 10.1186/s40478-015-0211-5.

[34]

J. P. Martinez-Barbera and R. Buslei, 'Adamantinomatous craniopharyngioma: pathology, molecular genetics and mouse models', *Journal of Pediatric Endocrinology and Metabolism*, vol. 28, no. 1–2, Jan. 2015, doi: 10.1515/jpem-2014-0442.

[35]

T. Goschzik et al., 'Genomic Alterations of Adamantinomatous and Papillary Craniopharyngioma', *Journal of Neuropathology & Experimental Neurology*, Jan. 2017, doi: 10.1093/jnen/nlw116.

[36]

A. M. Azarova, G. Gautam, and R. E. George, 'Emerging importance of ALK in neuroblastoma', *Seminars in Cancer Biology*, vol. 21, no. 4, pp. 267–275, Oct. 2011, doi: 10.1016/j.semcancer.2011.09.005.

[37]

E. A. Beierle, 'MYCN, Neuroblastoma and Focal Adhesion Kinase (FAK)', *Frontiers in bioscience (Elite edition)*, vol. 3 [Online]. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3171213/>

[38]

E. Bell, L. Chen, T. Liu, G. M. Marshall, J. Lunec, and D. A. Tweddle, 'MYCN oncoprotein targets and their therapeutic potential', *Cancer Letters*, vol. 293, no. 2, pp. 144–157, Jul. 2010, doi: 10.1016/j.canlet.2010.01.015.

[39]

T. Berry et al., 'The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma', *Cancer Cell*, vol. 22, no. 1, pp. 117–130, Jul. 2012, doi: 10.1016/j.ccr.2012.06.001.

[40]

G. M. Brodeur, 'Neuroblastoma: biological insights into a clinical enigma', *Nature Reviews Cancer*, vol. 3, no. 3, pp. 203–216, Mar. 2003, doi: 10.1038/nrc1014.

[41]

G. M. Brodeur and R. Bagatell, 'Mechanisms of neuroblastoma regression', *Nature Reviews Clinical Oncology*, vol. 11, no. 12, pp. 704–713, Dec. 2014, doi: 10.1038/nrclinonc.2014.168.

[42]

Garrett M. Brodeur, Robert C. Seeger, Manfred Schwab, Harold E. Varmus and J. Michael Bishop, 'Amplification of N-myc in Untreated Human Neuroblastomas Correlates with Advanced Disease Stage', *Science*, vol. 224, no. 4653, pp. 1121–1124, 1984 [Online]. Available: <http://www.jstor.org/stable/1692440>

[43]

C. A. Burkhart et al., 'Effects of MYCN Antisense Oligonucleotide Administration on Tumorigenesis in a Murine Model of Neuroblastoma', *JNCI Journal of the National Cancer Institute*, vol. 95, no. 18, pp. 1394–1403, Sep. 2003, doi: 10.1093/jnci/djg045.

[44]

L. Chen et al., 'p53 Is a Direct Transcriptional Target of MYCN in Neuroblastoma', *Cancer Research*, vol. 70, no. 4, pp. 1377–1388, Feb. 2010, doi: 10.1158/0008-5472.CAN-09-2598.

[45]

I. Cossu et al., 'Neuroblastoma-targeted nanocarriers improve drug delivery and penetration, delay tumor growth and abrogate metastatic diffusion', *Biomaterials*, vol. 68, pp. 89–99, Nov. 2015, doi: 10.1016/j.biomaterials.2015.07.054.

[46]

A. E. Evans, E. Baum, and R. Chard, 'Do infants with stage IV-S neuroblastoma need treatment?', *Archives of Disease in Childhood*, vol. 56, no. 4, pp. 271–274, Apr. 1981, doi: 10.1136/adc.56.4.271.

[47]

L. Guglielmi et al., 'MYCN gene expression is required for the onset of the differentiation programme in neuroblastoma cells', *Cell Death & Disease*, vol. 5, no. 2, pp. e1081–e1081, Feb. 2014, doi: 10.1038/cddis.2014.42.

[48]

M. Huang and W. A. Weiss, 'Neuroblastoma and MYCN', *Cold Spring Harbor Perspectives in Medicine*, vol. 3, no. 10, pp. a014415–a014415, Oct. 2013, doi: 10.1101/cshperspect.a014415.

[49]

K. Huber, C. Kalcheim, and K. Unsicker, 'The development of the chromaffin cell lineage from the neural crest', *Autonomic Neuroscience*, vol. 151, no. 1, pp. 10–16, Nov. 2009, doi: 10.1016/j.autneu.2009.07.020.

[50]

Z. Liu and C. J. Thiele, 'ALK and MYCN: When Two Oncogenes Are Better than One', *Cancer Cell*, vol. 21, no. 3, pp. 325–326, Mar. 2012, doi: 10.1016/j.ccr.2012.03.004.

[51]

A. Marabelle, V. Sapin, R. Rousseau, B. Periquet, F. Demeocq, and J. Kanold, 'Hypercalcemia and 13-*cis*-retinoic acid in post-consolidation therapy of neuroblastoma', *Pediatric Blood & Cancer*, vol. 52, no. 2, pp. 280–283, Feb. 2009, doi: 10.1002/pbc.21768.

[52]

K. K. Matthay et al., 'Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-*cis*-Retinoic Acid', *New England Journal of Medicine*, vol. 341, no. 16, pp. 1165–1173, Oct. 1999, doi: 10.1056/NEJM199910143411601.

[53]

Y. P. Mossé et al., 'Identification of ALK as a major familial neuroblastoma predisposition gene', *Nature*, vol. 455, no. 7215, pp. 930–935, Oct. 2008, doi: 10.1038/nature07261.

[54]

F. Pastorino et al., 'Ligand-Targeted Liposomal Therapies of Neuroblastoma', *Current Medicinal Chemistry*, vol. 14, no. 29, pp. 3070–3078, Dec. 2007, doi: 10.2174/092986707782793916.

[55]

J. Qiao et al., 'PI3K/AKT and ERK regulate retinoic acid-induced neuroblastoma cellular differentiation', *Biochemical and Biophysical Research Communications*, vol. 424, no. 3, pp. 421–426, Aug. 2012, doi: 10.1016/j.bbrc.2012.06.125.

[56]

C. P. Reynolds, K. K. Matthay, J. G. Villablanca, and B. J. Maurer, 'Retinoid therapy of high-risk neuroblastoma', *Cancer Letters*, vol. 197, no. 1–2, pp. 185–192, Jul. 2003, doi: 10.1016/S0304-3835(03)00108-3.

[57]

M. Schwab, 'MYCN in neuronal tumours', *Cancer Letters*, vol. 204, no. 2, pp. 179–187, Feb. 2004, doi: 10.1016/S0304-3835(03)00454-3.

[58]

N. Sidell, 'Retinoic Acid-Induced Growth Inhibition and Morphologic Differentiation of Human Neuroblastoma Cells In Vitro', *JNCI: Journal of the National Cancer Institute*, 1982, doi: 10.1093/jnci/68.4.589.

[59]

B. Vogelstein, N. Papadopoulos, V. E. Velculescu, S. Zhou, L. A. Diaz, and K. W. Kinzler, 'Cancer Genome Landscapes', *Science*, vol. 339, no. 6127, pp. 1546–1558, Mar. 2013, doi: 10.1126/science.1235122.

[60]

J. H. Wright, 'NEUROCYTOMA OR NEUROBLASTOMA, A KIND OF TUMOR NOT GENERALLY RECOGNIZED', *The Journal of Experimental Medicine*, vol. 12, no. 4, 1910, doi: 10.1084/jem.12.4.556.

[61]

Yang, LiqunKe, Xiao-XueXuan, FanTan, JuanHou, Jianbing, 'PHOX2B Is Associated with Neuroblastoma Cell Differentiation', *Cancer Biotherapy & Radiopharmaceuticals*, vol. 31, pp. 44–51, doi: 10.1089/cbr.2015.1952. [Online]. Available: https://search.proquest.com/docview/1776665507?rfr_id=info%3Axri%2Fsid%3Aprim

[62]

S. Zhu et al., 'Activated ALK Collaborates with MYCN in Neuroblastoma Pathogenesis', *Cancer Cell*, vol. 21, no. 3, pp. 362–373, Mar. 2012, doi: 10.1016/j.ccr.2012.02.010.

[63]

H. Hasle and C. M. Niemeyer, 'Advances in the prognostication and management of advanced MDS in children', *British Journal of Haematology*, vol. 154, no. 2, pp. 185–195, Jul. 2011, doi: 10.1111/j.1365-2141.2011.08724.x.

[64]

C. M. Niemeyer and C. P. Kratz, 'Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options', *British Journal of Haematology*, vol. 140, no. 6, pp. 610–624, Mar. 2008, doi: 10.1111/j.1365-2141.2007.06958.x.

[65]

T. Wegman-Ostrosky and S. A. Savage, 'The genomics of inherited bone marrow failure: from mechanism to the clinic', *British Journal of Haematology*, vol. 177, no. 4, pp. 526–542, May 2017, doi: 10.1111/bjh.14535.

[66]

K. Strebhardt and A. Ullrich, 'Paul Ehrlich's magic bullet concept: 100 years of progress', *Nature Reviews Cancer*, vol. 8, no. 6, pp. 473–480, Jun. 2008, doi: 10.1038/nrc2394.

[67]

C. M. Koebel et al., 'Adaptive immunity maintains occult cancer in an equilibrium state', *Nature*, vol. 450, no. 7171, pp. 903–907, Dec. 2007, doi: 10.1038/nature06309.

[68]

C. L. Mackall, M. S. Merchant, and T. J. Fry, 'Immune-based therapies for childhood cancer', *Nature Reviews Clinical Oncology*, vol. 11, no. 12, pp. 693–703, Dec. 2014, doi: 10.1038/nrclinonc.2014.177.

[69]

C. A. Klebanoff, S. A. Rosenberg, and N. P. Restifo, 'Prospects for gene-engineered T cell immunotherapy for solid cancers', *Nature Medicine*, vol. 22, no. 1, pp. 26–36, Jan. 2016, doi: 10.1038/nm.4015.

[70]

'Nature Reviews Immunology', vol. 12, no. 4, 2012 [Online]. Available:
<https://www.nature.com/nri/volumes/12/issues/4>

[71]

R. G. Majzner, S. Heitzeneder, and C. L. Mackall, 'Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers', *Cancer Cell*, vol. 31, no. 4, pp. 476–485, Apr. 2017, doi: 10.1016/j.ccell.2017.03.002.

[72]

M. F. Greaves and J. Wiemels, 'Origins of chromosome translocations in childhood leukaemia', *Nature Reviews Cancer*, vol. 3, no. 9, pp. 639–649, Sep. 2003, doi: 10.1038/nrc1164.

[73]

A. Zelent, M. Greaves, and T. Enver, 'Role of the TEL-AML1 fusion gene in the molecular pathogenesis of childhood acute lymphoblastic leukaemia', *Oncogene*, vol. 23, no. 24, pp. 4275–4283, May 2004, doi: 10.1038/sj.onc.1207672.

[74]

R. K. Slany, 'The molecular mechanics of mixed lineage leukemia', *Oncogene*, vol. 35, no. 40, pp. 5215–5223, Oct. 2016, doi: 10.1038/onc.2016.30.

[75]

T. A. Milne, 'Mouse models of MLL leukemia: recapitulating the human disease', *Blood*, vol. 129, no. 16, pp. 2217–2223, Apr. 2017, doi: 10.1182/blood-2016-10-691428.

[76]

M. Sadelain, I. Rivière, and S. Riddell, 'Therapeutic T cell engineering', *Nature*, vol. 545, no. 7655, pp. 423–431, May 2017, doi: 10.1038/nature22395.

[77]

L. A. Johnson and C. H. June, 'Driving gene-engineered T cell immunotherapy of cancer', *Cell Research*, vol. 27, no. 1, pp. 38–58, Jan. 2017, doi: 10.1038/cr.2016.154.

[78]

C. S. M. Yong, V. Dardalhon, C. Devaud, N. Taylor, P. K. Darcy, and M. H. Kershaw, 'CAR T-cell therapy of solid tumors', *Immunology and Cell Biology*, vol. 95, no. 4, pp. 356–363, Apr. 2017, doi: 10.1038/icb.2016.128.

[79]

J. Fisher et al., 'Avoidance of On-Target Off-Tumor Activation Using a Co-stimulation-Only Chimeric Antigen Receptor', *Molecular Therapy*, vol. 25, no. 5, pp. 1234–1247, May 2017, doi: 10.1016/j.ymthe.2017.03.002.

[80]

C. E. Brown et al., 'Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy', *New England Journal of Medicine*, vol. 375, no. 26, pp. 2561–2569, Dec. 2016, doi: 10.1056/NEJMoa1610497.

[81]

L. Morsut et al., 'Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors', *Cell*, vol. 164, no. 4, pp. 780–791, Feb. 2016, doi: 10.1016/j.cell.2016.01.012.

[82]

J. Rasaiyaah, C. Georgiadis, R. Preece, U. Mock, and W. Qasim, 'TCR $\alpha\beta$ /CD3 disruption enables CD3-specific antileukemic T cell immunotherapy', *JCI Insight*, vol. 3, no. 13, Jul. 2018, doi: 10.1172/jci.insight.99442.

[83]

S. Ghorashian, P. Amrolia, and P. Veys, 'Open access? Widening access to chimeric antigen receptor (CAR) therapy for ALL', *Experimental Hematology*, vol. 66, pp. 5–16, Oct. 2018, doi: 10.1016/j.exphem.2018.07.002.

[84]

W. Qasim et al., 'Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells', *Science Translational Medicine*, vol. 9, no. 374, Jan. 2017, doi: 10.1126/scitranslmed.aaj2013.

[85]

C. G. Hubert et al., 'A Three-Dimensional Organoid Culture System Derived from Human Glioblastomas Recapitulates the Hypoxic Gradients and Cancer Stem Cell Heterogeneity of Tumors Found', *Cancer Research*, vol. 76, no. 8, pp. 2465–2477, Apr. 2016, doi: 10.1158/0008-5472.CAN-15-2402.

[86]

A. Richmond and Y. Su, 'Mouse xenograft models vs GEM models for human cancer therapeutics', *Disease Models and Mechanisms*, vol. 1, no. 2–3, pp. 78–82, Sep. 2008, doi: 10.1242/dmm.000976.

[87]

T. N. Phoenix et al., 'Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype', *Cancer Cell*, vol. 29, no. 4, pp. 508–522, Apr. 2016, doi: 10.1016/j.ccell.2016.03.002.

[88]

B. Lu, B. Green, J. Farr, F. Lopes, and T. Van Raay, 'Wnt Drug Discovery: Weaving Through the Screens, Patents and Clinical Trials', *Cancers*, vol. 8, no. 9, Sep. 2016, doi: 10.3390/cancers8090082.

[89]

P. A. Northcott, A. Korshunov, S. M. Pfister, and M. D. Taylor, 'The clinical implications of medulloblastoma subgroups', *Nature Reviews Neurology*, vol. 8, no. 6, pp. 340–351, Jun. 2012, doi: 10.1038/nrneurol.2012.78.

[90]

M. V. Niklison-Chirou et al., 'TAp73 is a marker of glutamine addiction in medulloblastoma', *Genes & Development*, vol. 31, no. 17, pp. 1738–1753, Sep. 2017, doi: 10.1101/gad.302349.117.

[91]

C. S. Hourigan and J. E. Karp, 'Minimal residual disease in acute myeloid leukaemia', *Nature Reviews Clinical Oncology*, vol. 10, no. 8, pp. 460–471, Aug. 2013, doi: 10.1038/nrclinonc.2013.100.

[92]

M. Kotrova, J. Trka, M. Kneba, and M. Brüggemann, 'Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?', *Molecular Diagnosis & Therapy*, vol. 21, no. 5, pp. 481–492, Oct. 2017, doi: 10.1007/s40291-017-0277-9.

[93]

D. O'Connor et al., 'Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia', *Journal of Clinical Oncology*, vol. 36, no. 1, pp. 34–43, Jan. 2018, doi: 10.1200/JCO.2017.74.0449.

[94]

A. Vora et al., 'Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial', *The Lancet Oncology*, vol. 14, no. 3, pp. 199–209, Mar. 2013, doi: 10.1016/S1470-2045(12)70600-9.

[95]

A. Vora et al., 'Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial', *The Lancet Oncology*, vol. 15, no. 8, pp. 809–818, Jul. 2014, doi: 10.1016/S1470-2045(14)70243-8.

[96]

S. P. Hunger and C. G. Mullighan, 'Acute Lymphoblastic Leukemia in Children', *New England Journal of Medicine*, vol. 373, no. 16, pp. 1541–1552, Oct. 2015, doi: 10.1056/NEJMra1400972.

[97]

D. O'Connor et al., 'Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia', *Journal of Clinical Oncology*, vol. 36, no. 1, pp. 34–43, Jan. 2018, doi: 10.1200/JCO.2017.74.0449.